Ozureprubart clinical trials
Also written JYB1904.
How each study uses ozureprubart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ozureprubart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Jemincare (6) · RAPT Therapeutics, Inc., a member of the GSK plc group of companies (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test ozureprubart, phase 3 first.
- Jun 2027Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.Phase 3 · Jemincare
- Mar 2027Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food AllergyPhase 2 · RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Jul 2027Trial of JYB1904 Injection in Adolescent ParticipantsPhase 1 · Jemincare
- Oct 2027Trial of JYB1904 Injection in Patients With Perennial Allergic RhinitisPhase 2 · Jemincare
Studies
Open first, then newest update. How each study uses ozureprubart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.RecruitingPhase 3JemincareNCT07402213Written as JYB1904
- Trial of JYB1904 Injection in Adolescent ParticipantsNot yet recruitingPhase 1JemincareNCT07513857Written as JYB1904
- Trial of JYB1904 Injection in Patients With Perennial Allergic RhinitisNot yet recruitingPhase 2JemincareNCT07459452Written as JYB1904
- Trial of JYB1904 in Chronic Spontaneous Urticaria.RecruitingPhase 2JemincareNCT06509334Written as JYB1904
- Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food AllergyActive, not recruitingPhase 2RAPT Therapeutics, Inc., a member of the GSK plc group of companiesNCT07220811Written as RPT904
- Trial of JYB1904 in Patients With Allergic AsthmaCompletedPhase 2JemincareNCT06438757Written as JYB1904
- Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese SubjectsCompletedPhase 1JemincareNCT05449535Written as JYB1904
Codes
What other systems call ozureprubart · ClinicalTrials.gg INT014954
- UNII (FDA) 4ZR9JAX9EGOZUREPRUBARTOne source FDA
- NCI Thesaurus C206960OzureprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4ZR9JAX9EG | OZUREPRUBART | One source FDA |
| NCI Thesaurus | C206960 | Ozureprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.